Biochemical effects in brain of low doses of haloperidol are qualitatively similar to those of high doses

European Neuropsychopharmacology

Volumn 12, Issue 5, 2002, Pages 379-386

  Marcus, M M ^a   Malmerfelt, A ^a   Nyberg, S ^b   Svensson, T H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Fos protein; Immunohistochemistry; Nucleus accumbens core; Nucleus accumbens shell; Schizophrenia; Voltammetry

Indexed keywords

DOPAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; PARGYLINE;

ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DOPAMINE UPTAKE; DOSE RESPONSE; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RAT;

AMYGDALA; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CORPUS STRIATUM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; IMMUNOHISTOCHEMISTRY; MALE; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0036788856     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(02)00048-2     Document Type: Article

References (45)

1. Aggleton J.P. The contribution of the amygdala to normal and abnormal emotional states. Trends Neurosci. 16:1993;328-333.
2. Alheid G.F., Heimer L. New perspectives in basal forebrain organization of special relevance for neuropsychiatric disorders: the striatopallidal, amygdaloid, and corticopetal components of substantia innominata. Neuroscience. 27:1988;1-39.
3. Alvir J.M., Lieberman J.A., Safferman A.Z., Schwimmer J.L., Schaaf J.A. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N. Engl. J. Med. 329:1993;162-167.
4. Brar J.S., Chengappa K.N., Parepally H., Sandman A.R., Kreinbrook S.B., Sheth S.A., Ganguli R. The effects of clozapine on negative symptoms in patients with schizophrenia with minimal positive symptoms. Ann. Clin. Psychiatry. 9:1997;227-234.
5. Breier A., Buchanan R.W., Kirkpatrick B., Davis O.R., Irish D., Summerfelt A., Carpenter W.T. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am. J. Psychiatry. 151:1994;20-26.
6. Brog J.S., Salyapongse A., Deutch A.Y., Zahm D.S. The patterns of afferent innervation of the core and shell in the 'accumbens' part of the rat ventral striatum: immunohistochemical detection of retrogradely transported fluoro-gold. J. Comp. Neurol. 338:1993;255-278.
7. Casey D.E. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (Berl.). 99:(Suppl.):1989;S47-S53.
8. Chergui K., Nomikos G.G., Mathe J.M., Gonon F., Svensson T.H. Burst stimulation of the medial forebrain bundle selectively increase Fos-like immunoreactivity in the limbic forebrain of the rat. Neuroscience. 72:1996;141-156.
9. Conley R.R., Schulz S.C., Baker R.W., Collins J.F., Bell J.A. Clozapine efficacy in schizophrenic nonresponders. Psychopharmacol. Bull. 24:1988;269-274.
10. Deutch A.Y. Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease. J. Neural Transm. Gen. Sect. 91:1993;197-221. Review; 146 refs.
11. Deutch A.Y., Lee M.C., Iadarola M.J. Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol. Cell. Neurosci. 3:1992;332-341.
12. Farde L., Nordström A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry. 49:1992;538-544.
13. Farde L., Wiesel F.A., Halldin C., Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiatry. 45:1988;71-76.
14. Fink-Jensen A., Kristensen P. Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain. Neurosci. Lett. 182:1994;115-118.
15. Gallagher M., Chiba A.A. The amygdala and emotion. Curr. Opin. Neurobiol. 6:1996;221-227.
16. Geddes J., Freemantle N., Harrison P., Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br. Med. J. 321:2000;1371-1376.
17. Gonon F., Buda M., Pujol J.F. Treated carbon fibre electrodes for measuring catechols and ascorbic acid. Marsden C.A., Measurement of Neurotransmittor Release In Vivo. 1984;153-171 Wiley, Chichester, UK.
18. Gonon F.G. Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience. 24:1988;19-28.
19. Heimer L., Alheid G.F., de Olmos J.S., Groenewegen H.J., Haber S.N., Harlan R.E., Zahm D.S. The accumbens: beyond the core-shell dichotomy. J. Neuropsychiatr. Clin. Neurosci. 9:1997;354-381.
20. Hughes P., Dragunow M. Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacol. Rev. 47:1995;133-178.
21. Idänpään-Heikkilä J., Alhava E., Olkinuora M., Palva I.P. Agranulocytosis during treatment with clozapine. Eur. J. Clin. Pharmacol. 11:1977;193-198.
22. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 45:1988;789-796.
23. Kapur S., Remington G., Jones C., Wilson A., DaSilva J., Houle S., Zipursky R. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am. J. Psychiatry. 153:1996;948-950. see comments.
24. Kapur S., Wadenberg M.L., Remington G. Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench. Can. J. Psychiatry. 45:2000;241-246.
25. Lindenmayer J.P., Grochowski S., Mabugat L. Clozapine effects on positive and negative symptoms: a six-month trial in treatment-refractory schizophrenics. J. Clin. Psychopharmacol. 14:1994;201-204.
26. Marcus M.M., Nomikos G.G., Svensson T.H. Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens. Eur. Neuropsychopharmacol. 6:1996;29-38.
27. Marcus M.M., Nomikos G.G., Svensson T.H. Effects of atypical antipsychotic drugs on dopamine output in the shell and core of the nucleus accumbens: role of 5-HT(2A) and alpha(1)-adrenoceptor antagonism. Eur. Neuropsychopharmacol. 10:2000;245-253.
28. McEvoy J.P., Hogarty G.E., Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch. Gen. Psychiatry. 48:1991;739-745.
29. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25:1999;233-255.
30. Merchant K.M., Dorsa D.M. Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics. Proc. Natl. Acad. Sci. USA. 90:1993;3447-3451.
31. Mogenson G.J., Jones D.L., Yim C.Y. From motivation to action: functional interface between the limbic system and the motor system. Prog. Neurobiol. 14:1980;69-97.
32. Morgan J.I., Curran T. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Annu. Rev. Neurosci. 14:1991;421-451.
33. Nguyen T.V., Kosofsky B.E., Birnbaum R., Cohen B.M., Hyman S.E. Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc. Natl. Acad. Sci. USA. 89:1992;4270-4274.
34. Nordström A.L., Farde L., Halldin C. Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl.). 106:1992;433-438.
35. Nyberg S., Farde L., Halldin C., Dahl M.L., Bertilsson L. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am. J. Psychiatry. 152:1995;173-178.
36. Paxinos G., Watson C. 4th Edition The Rat Brain in Stereotaxic Coordinates. 1998;Academic Press, San Diego.
37. Pinna A., Morelli M. Differential induction of Fos-like-immunoreactivity in the extended amygdala after haloperidol and clozapine. Neuropsychopharmacology. 21:1999;93-100.
38. Robertson G.S., Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience. 46:1992;315-328.
39. Robertson G.S., Matsumura H., Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J. Pharmacol. Exp. Ther. 271:1994;1058-1066.
40. Semba J., Sakai M., Miyoshi R., Mataga N., Fukamauchi F., Kito S. Differential expression of c-fos mRNA in rat prefrontal cortex, striatum, N. accumbens and lateral septum after typical and atypical antipsychotics: an in situ hybridization study. Neurochem. Int. 29:1996;435-442.
41. Stone C.K., Garve D.L., Griffith J., Hirschowitz J., Bennett J. Further evidence of a dose-response threshold for haloperidol in psychosis. Am. J. Psychiatry. 152:1995;1210-1212.
42. Wadenberg M.L., Kapur S., Soliman A., Jones C., Vaccarino F. Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl.). 150:2000;422-429. In process citation.
43. Wan W., Ennulat D.J., Cohen B.M. Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain. Brain Res. 688:1995;95-104.
44. Zaborszky L., Alheid G.F., Beinfeld M.C., Eiden L.E., Heimer L., Palkovits M. Cholecystokinin innervation of the ventral striatum: a morphological and radioimmunological study. Neuroscience. 14:1985;427-453.
45. Zahm D.S. An integrative neuroanatomical perspective on some subcortical substrates of adaptive responding with emphasis on the nucleus accumbens. Neurosci. Biobehav. Rev. 24:2000;85-105.